Placental aromatase and elevated SHBG levels have been postulated to reduce fetal exposure to maternal androgens (26–28), and could be the factors explaining the differences in VCB and maternal testosterone levels in pregnancies with T2D. Here, CYP19A1 is linked to type 2 diabetes mellitus.